All In Biotech

Drug Trial Radar · NCT07565428

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Minerva NeurosciencesIndustry
Sponsor type
Industry
First posted
May 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate of Roluperidone and antipsychotic medications.

Conditions

  • Negative Symptoms of Schizophrenia

Interventions

  • RoluperidoneDrug

    Roluperidone 64 mg

  • risperidoneDrug

    risperidone 4 mg

  • aripiprazoleDrug

    aripiprazole 10 mg

  • olanzapineDrug

    olanzapine 10 mg

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS)Time frame: Phase A: Screening, Baseline, Weeks 2, 4, 8, 12

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Innovations, Inc. dba CITrials

    Bellflower, California · Recruiting

  • ProScience Research Group

    Culver City, California · Recruiting

  • Collaborative Neuroscience Research, LLC

    Garden Grove, California · Recruiting

  • Clinical Innovations, Inc. dba CITrials

    Riverside, California · Recruiting

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida · Recruiting

  • Behavioral Clinical Research, Inc.

    Hollywood, Florida · Recruiting

  • ForCare Clinical Research

    Tampa, Florida · Recruiting

  • Atlanta Center for Medical Research, LLC

    Atlanta, Georgia · Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia · Recruiting

  • CBH Health, LLC dba CenExel

    Gaithersburg, Maryland · Recruiting

  • Hassman Research Institute, LLC dba CenExel

    Marlton, New Jersey · Recruiting

  • New York State Psychiatric Institute

    New York, New York · Recruiting

  • Pillar Clinical Research, LLC

    Richardson, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.